Page 609«..1020..608609610611..620630..»

New Treatments and Tips for Dealing With Blood Cancer – Curetoday.com

Posted: October 28, 2021 at 2:55 am

Did you know that every three minutes someone receives a diagnosis of a blood cancer? According to the National Foundation for Cancer Research, blood cancers account for nearly 10% of new cancer diagnoses in the United States annually. That means that approximately 178,520 people will receive a diagnosis this year most commonly with leukemia, lymphoma or myeloma. And although survival rates have increased dramatically over the past 20 years, theres still a long way to go when it comes to this patient population.

In this special issue of CURE, youll read about some of the research going on in blood cancer right now, including new treatment options for acute myeloid leukemia and a novel therapy using BK virus-specific T cells to treat BK virus-associated hemorrhagic cystitis (a painful side effect of stem cell transplants).

Dive into the issue for two patient stories, one about a three-time acute lymphoblastic leukemia survivor who now works as a nurse on the bone marrow transplant floor at Barnes-Jewish Hospital in St. Louis. This year also marks the 20th anniversary of the Food and Drug Administrations approval of Gleevec (imatinib mesylate), the tyrosine kinase inhibitor that saved Mel Mann. Who is Mel Mann? He is the longest-living survivor who was treated with the drug as a part of a clinical trial for chronic myeloid leukemia.

And because cancer is not a disease one should have to face alone, our cover story looks at the responsibilities and experiences of caregivers to patients with blood cancer. Not only will you read about what theyve gone through, but youll also find extra resources and tips for navigating the patient-caregiver relationship.

As always, thank you for reading.

For more news on cancer updates, research and education, dont forget tosubscribe to CUREs newsletters here.

View original post here:
New Treatments and Tips for Dealing With Blood Cancer - Curetoday.com

Posted in Stem Cell Treatments | Comments Off on New Treatments and Tips for Dealing With Blood Cancer – Curetoday.com

Managing superficial pyoderma with light therapy – DVM 360

Posted: October 28, 2021 at 2:55 am

Phovia is highly effective for treating superficial and deep skin infections.

This article is sponsored by Vetoquinol.

Superficial bacterial folliculitis, also called superficial pyoderma, is a commonly diagnosed dermatological condition in dogs.1,2 These infections are secondary to primary conditions affecting normal skin barrier function (eg, allergic skin disease, trauma, burns), keratinization (eg, nutritional deficiency, liver disease), and immune regulation (eg, neoplasia, autoimmunity, endocrinopathy).2 Cats less commonly develop superficial pyoderma perhaps because of decreased adhesion of staphylococci to feline corneocytes, but the primary issues causing infection are similar to those seen in dogs.3-8

The primary pathogen associated with superficial pyoderma in dogs and cats is a normal resident of the skin, Staphylococcus pseudintermedius, but other flora may be involved.2,8-12 As the normal homeostasis of this organism is disrupted from a primary disease, these gram-positive cocci invade deeper regions of the epidermis and hair follicle epithelium, increase in number, and enhance inflammation.

Classical clinical lesions of superficial pyoderma include papules and pustules that may eventually progress to alopecia, epidermal collarettes, scales, and crusts. Often the skin is erythematous and pruritic. Chronic cases may demonstrate lichenification, hyperpigmentation, and scarring alopecia from long-standing inflammation and infection.2 Cats may develop even more unique cutaneous reaction patterns and skin lesionsespecially when allergic skin disease is presentincluding miliary dermatitis, eosinophilic plaques, rodent ulcers, and eosinophilic granulomas.5

Identifying and addressing the primary disease is paramount in achieving complete, permanent resolution of the superficial pyoderma. Therefore, treatment is multifactorial and aimed at addressing the primary disease, reducing skin inflammation, and treating the infection directly. Current guidelines for the treatment of superficial pyoderma in dogs recommend the use of topical antimicrobials as sole therapy whenever possible; however, overuse of systemic antibiotics remains common.2,13-16

Topical therapy has many benefits including direct antimicrobial effects without use of an antibiotic, reduction in antibiotic-resistant bacterial populations, restoration of the normal skin barrier, enhancement of skin hydration, physical removal of keratinous debris, and removal of offending allergens from the haircoat.2,14 However, topical therapy is met with challenges that impede clinical application. Adherence is the biggest concern when recommending topical therapy to pet owners. Frequent bathing or application of medicated solutions to the skin can be difficult when busy owner lifestyles combine with a nonadherent patient. Skin inflammation can be painful and animals may be resistant to topical therapy. Cats are fastidious groomers and may lick away a medicated topical therapy before it can achieve appropriate contact time. Additionally, some topical agents can cause oral erosions and ulcerations or even gastrointestinal disturbance when groomed off. For these reasons, systemic antibiotics continue to be a common prescribing practice for superficial pyoderma.

All antibiotic use, despite duration or frequency, contributes to the development of antibiotic-resistant bacterial populations on the animal and in the environment.17-19 From that very first dose, bacteria are constantly evolving to implement inherent and acquired resistance mechanisms necessary for survival. One well-recognized mechanism is oxacillin resistance through the mecA gene, which produces a penicillin-binding protein receptor with poor affinity for -lactam antibiotics.2,14,15,20-23 Even more concerning than these oxacillin-resistant strains are those that develop multidrug resistance, which is defined as resistance to 3 or more antibiotic drug classes. This may happen over time with repeated antibiotic exposure or after a single dose of certain antibiotics such as fluorinated quinolones.2,20,23-25 The continued emergence of antibiotic-resistant bacteria inhibits the successful treatment of bacterial infections in pets and humans. As veterinarians consider how their antibiotic use contributes to this growing pandemic, they must look for alternative, safe, effective, affordable, and convenient antibacterial treatment modalities.

Phovia as a solution

Investigation into the photobiological effects of light therapy has been ongoing for the past 50 years. Photobiomodulation (PBM) therapy is a type of light treatment that uses visible or near infrared light to promote therapeutic benefits including induction of tissue healing and regeneration and inhibition of biological responses that induce pain or inflammation. The treatment distance, wavelength, fluence, pulse parameters, spot size, and irradiation time influence the effects of light energy on tissue. Visible light with wavelengths ranging from 400 to 700 nm can stimulate positive photobiomodulatory effects that promote wound healing, reduce inflammation and pain, modulate stem cell populations, and reduce bacterial contamination of wounds.26,27

Once visible light enters the skin, it is absorbed by the cells and initiates chemical changes dependent on the wavelength (or color) of light and the chromophore within the skin.27 Within each cell, membrane-bound organelles called mitochondria contain chromophores that absorb the light energy and begin making energy (adenosine triphosphate; ATP) via activation of cytochrome c oxidase. Outcomes of the mitochondrial respiratory pathway activation include stimulation of secondary messenger pathways, production of transcription factors and growth factors, and increased ATP production. However, excessive light energy exposure will overstimulate mitochondrial respiration and cause expenditure of all ATP reserves, which creates oxidative stress resulting in damaging elevations of nitric oxide, production of harmful free radicals, and activation of cytotoxic mitochondrial-signaling pathways leading to apoptosis.27,28 This is why creating PBM therapy protocols is important for targeting the beneficial effects while avoiding unintended harm.

Specific benefits of light energy within the visible light spectrum can be broken down into each color of light. Blue light (400-500 nm) has a lower penetration depth and primarily interacts with keratinocytes, reduces bacterial adhesion and growth, and increases intracellular calcium and osteoblast differentiation.29-31 Green light (495-570 nm) affects the superficial tissue and alters melanogenesis, reduces hyperpigmentation of the skin, and reduces tissue swelling.29,30 Red light (600-750 nm) penetrates deeper into the dermis and subcutis where it acts on cellular mitochondria to reduce inflammation and promote collagen synthesis through fibroblast proliferation and production of transforming growth factor-, fibroblast growth factor, platelet derived growth factor, and others.26-28,32,33 Red light has proliferative effects on mesenchymal stem cells and induces proliferation of epithelial colony forming units important for tissue repair and regeneration.34,35

Phovia, sold by Vetoquinol, is a form of fluorescent PBM therapy utilizing a blue light emitting diode (LED lamp, 400-460 nm) and topical photoconverter gel that emits low-energy fluorescent light (510-600 nm) when illuminated by the LED lamp.36,37 This interaction results in the formation of multiple wavelengths of visible light, each with a unique depth of penetration and effect on the tissue as described above. Application is fast and simple. The affected skin may be clipped free of hair and cellular debris removed with gentle cleaning. The skin is allowed to dry before application of the photoconverter gel. Just prior to application, 1 ampule of fluorescence chromophore gel is added to 1 container of photoconverter carrier gel and mixed thoroughly. The mixture is applied in a 2-mm layer to the affected skin, and the LED lamp is held 5 cm above the lesion and used to illuminate the area for 2 minutes. The gel is wiped away using saline-soaked gauze. The application can be repeated immediately after 5 to 10 minutes of rest or a second application can occur a few days later. Twice-weekly applications are continued until the wound is healed. Appropriate eyewear is required to protect the operator from the intensely bright light. Application is pain free and stress free for the patient, so sedation is not typically required.

Benefits of Phovia

Phovia shows great promise as a safe, effective therapy for treatment of numerous inflammatory dermatoses in dogs including superficial pyoderma,38 deep pyoderma,39 perianal fistula,40 interdigital dermatitis,41 calcinosis cutis,42 acute traumatic wounds,43 chronic wounds,37 surgical wounds,44 and otitis externa.45 Phovia as a sole therapy speeds time to healing by 36% in canine superficial pyoderma as compared with dogs receiving oral antibiotics alone.38 In one study, dogs with superficial pyoderma were treated with Phovia alone or with an oral antibiotic alone. Dogs treated twice weekly with Phovia demonstrated complete clinical healing in about 2.3 weeks (P < .05)whereas dogs receiving oral antibiotic healed in about 3.75 weeks.38 Additionally, Phovia speeds time to healing by nearly 50% in deep pyoderma when used with an oral antibiotic (5.7 weeks of treatment) compared with dogs receiving only oral antibiotic (11.7 weeks of treatment).39 The ability of this fluorescent PBM therapy to eliminate or significantly reduce duration of exposure to antibiotics will decrease the spread of antibiotic-resistant bacterial strains within pets and humans.

Phovias high safety profile makes it a beneficial tool to implement in everyday practice. Training the veterinary team to communicate therapy benefits with clients as well as to perform treatments is fast and easy. Training the veterinary technicians to perform treatments will give the veterinarian time to examine other patients. A single back-to-back application takes about 15 minutes, so pet owners can be in and out of the clinic quickly; however, the 2 weekly treatments can be separated by a few days if the veterinarian prefers to evaluate the patient more frequently. Additionally, when used as a sole therapy, clients are not required to administer oral or topical medications at home. This greatly improves treatment adherence and success. Instruct clients to use once-daily smartphone photos to document improvement at home. This can be useful when deciding how many treatments to perform. Most cases of superficial pyoderma will resolve completely by the third treatment.38 It is a good idea to communicate to clients that 3 to 4 weekly treatments may be required.

Conclusion

Phovia is a versatile, innovative therapeutic approach to numerous types of dermatitis.36 It is easy to implement in general practice, and is safe, pain free, and affordable. Phovia is highly effective for superficial and deep skin infections and eliminates the need for clients to administer numerous at-home treatments. This greatly improves the pet-owner bond and treatment outcomes by promoting adherence. Phovia accelerates time to wound healing, which decreases duration of antibiotic exposure and may reduce risk of antibiotic resistance development in these cases.2,13,36-39 Phovias efficacy against antibiotic-susceptible and antibiotic-resistant bacteria shows promise as an alternative therapeutic approach that promotes the principles of antimicrobial stewardship.36 If you are interested in purchasing this medical device for your practice, contact your Vetoquinol service representative.

Amelia G. White, DVM, MS, DACVD is an associate clinical professor of dermatology at Auburn University College of Veterinary Medicine.

REFERENCES

Original post:
Managing superficial pyoderma with light therapy - DVM 360

Posted in Stem Cell Treatments | Comments Off on Managing superficial pyoderma with light therapy – DVM 360

Report by Mott Center researchers named NIEHS Extramural Paper of the Month – The South End

Posted: October 28, 2021 at 2:49 am

The National Institutes of Environmental Health Sciences has selected a study published by Wayne State University School of Medicine researchers as an Extramural Paper of the Month.

The paper, Paternal preconception phthalate exposure alters sperm methylome and embryonic programming, published in in the October issue of the journal Environment International by J. Richard Pilsner, Ph.D., professor and Robert J. Sokol, M.D., Endowed Chair of Molecular Obstetrics and Gynecology, and director of Molecular Genetics and Infertility for the C.S. Mott Center for Human Growth and Development; and Stephen Krawetz, Ph.D., the Charlotte B. Failing Professor of Fetal Therapy and Diagnosis, and associate director of the Mott Center, was selected by the NIEHS as a paper of the month for September.

The Extramural Papers of the Month are selected based on their important findings and potential for public health impact.

The researchers reported that male mice exposed to phthalates before conception had DNA methylation changes in sperm, which can be transferred to the next generation as altered gene expression in embryos. DNA methylation occurs when a chemical compound, called a methyl group, attaches to DNA, affecting whether a gene is turned on or off.

They exposed male mice to either a low or high level of di(2-ethylhexyl) phthalate for two sperm production cycles, or 67 days. Following exposure, they mated the mice with unexposed females. They then assessed genome-wide methylation in sperm, embryos and extra-embryonic tissues, which support the developing embryo.

Compared with unexposed controls, paternal preconception DEHP exposure altered methylation in 704 sperm gene regions, 1,716 embryo gene regions, and 3,181 extra-embryonic gene regions. Of these, 29 gene regions overlapped between sperm and embryonic tissues, suggesting methylation changes related to paternal DEHP exposure may be transmitted to the next generation. The researchers also identified changes in gene expression in embryos in both exposure groups compared with controls. Many of the altered genes were related to pathways important in development.

The researchers said their results indicate that preconception is a sensitive window in which phthalate exposure alters sperm methylation and embryo gene expression in ways that may influence offspring health and development.

Others involved in the research and subsequent publication include Oladele Oluwayiose, a doctoral student at the University of Massachusetts Amherst; Chelsea Marcho, Department of Environmental Health Sciences, University of Massachusetts Amherst; Haotian Wu, Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University; Alexander Suvorov, Department of Environmental Health Sciences, University of Massachusetts Amherst; Emily Houle, Department of Environmental Health Sciences, University of Massachusetts Amherst; and Jesse Mager, Department of Veterinary and Animal Sciences, University of Massachusetts Amherst.

Read more from the original source:
Report by Mott Center researchers named NIEHS Extramural Paper of the Month - The South End

Posted in Molecular Genetics | Comments Off on Report by Mott Center researchers named NIEHS Extramural Paper of the Month – The South End

Acer Therapeutics and Relief Therapeutics Announce Issuance of U.S. Patent 11154521 Covering ACER-001 Formulation – Stockhouse

Posted: October 28, 2021 at 2:49 am

NEWTON, Mass. and GENEVA, Switzerland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (Acer”) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) (Relief”), today announced that the U.S. Patent and Trademark Office (USPTO) has issued a new U.S. patent to Acer for certain claims related to ACER-001 (sodium phenylbutyrate). Patent 11,154,521 covers pharmaceutical composition claims related to ACER-001’s taste-masked, multi-particulate dosage formulation for oral administration. The newly issued patent has an expiration date in 2036.

We are extremely pleased that our ACER-001 formulation patent has been issued, adding key protection to our growing intellectual property portfolio for ACER-001 as we continue to advance its development to potentially treat patients with Urea Cycle Disorders (UCDs), Maple Syrup Urine Disease (MSUD) and other possible indications,” said Jeff Davis, Chief Business Officer at Acer. This patent issuance is an important step in our pursuit of possible ACER-001 commercialization, and we intend to submit it for listing by the U.S. Food and Drug Administration (FDA) in its Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book, should ACER-001 receive marketing approval.”

Jack Weinstein, Chief Financial Officer and Treasurer of Relief, added, In parallel to the patent application efforts in the U.S., Acer and Relief are pursuing similar claims in the European Patent Office to cover ACER-001 as we continue to execute on our plan to submit a Marketing Authorization Application for ACER-001 for the treatment of patients with UCDs in Europe in Q2/Q3 2022.”

Parties interested in the ACER-001 program for UCDs may sign up for updates at: https://www.acertx.com/rare-disease-research/acer-001-for-urea-cycle-disorders-ucds/

ACER-001 is an investigational product candidate which has not been approved by FDA, the European Medicines Agency (EMA), or any other regulatory authority. There can be no assurance that this product candidate will receive regulatory authority approval for marketing in any territory or become commercially available for the indications under investigation.

About UCDs UCDs are a group of disorders caused by genetic mutations that result in a deficiency in one of the six enzymes that catalyze the urea cycle, which can lead to an excess accumulation of ammonia in the bloodstream, a condition known as hyperammonemia. Acute hyperammonemia can cause lethargy, somnolence, coma, and multi-organ failure, while chronic hyperammonemia can lead to headaches, confusion, lethargy, failure to thrive, behavioral changes, and learning and cognitive deficits. Common symptoms of both acute and chronic hyperammonemia also include seizures and psychiatric symptoms.1,2 The current treatment of patients with UCDs consists of dietary management to limit ammonia production in conjunction with medications that provide alternative pathways for the removal of ammonia from the bloodstream. Some patients may also require individual branched-chain amino acid supplementation.

Current medical treatments for patients with UCDs include nitrogen scavengers, RAVICTI® and BUPHENYL®, in which the active pharmaceutical ingredients are glycerol phenylbutyrate and sodium phenylbutyrate, respectively. According to a 2016 study by Shchelochkov et al., published in Molecular Genetics and Metabolism Reports, while nitrogen scavenging medications have been shown to be effective in helping to manage ammonia levels in some patients with UCDs, non-compliance with treatment is common. Reasons referenced for non-compliance associated with some available medications include unpleasant taste, frequency with which medication must be taken, required number of pills, and the high cost of the medication.3

About ACER-001 ACER-001 (sodium phenylbutyrate) is being developed for the treatment of various inborn errors of metabolism, including UCDs and MSUD. ACER-001 is a nitrogen-binding agent in development for use as adjunctive therapy in the chronic management of patients with UCDs involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). The formulation is a multi-particulate dosage formulation for oral administration consisting of a core center, a layer of active drug, and a taste-masked coating designed to avoid the bitter taste of sodium phenylbutyrate in the mouth while quickly dissolving in the low pH of the stomach. The ACER-001 NDA for UCDs is currently under FDA review with a PDUFA target action date of June 5, 2022. ACER-001 is also being developed for MSUD and has been granted orphan drug designation by the FDA for this indication. ACER-001 is an investigational product candidate which has not been approved by FDA, the European Medicines Agency (EMA), or any other regulatory authority.

About Acer Therapeutics Inc. Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer’s pipeline includes four programs: ACER-001 (sodium phenylbutyrate) for treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); ACER-801 (osanetant) for treatment of induced Vasomotor Symptoms (iVMS); EDSIVO (celiprolol) for treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. Each of Acer’s product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA. In March 2021, Acer entered into a Collaboration and License Agreement with Relief for development and commercialization of ACER-001. For more information, visit http://www.acertx.com.

About RELIEF THERAPEUTICS Holding SA Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale. Relief’s lead drug candidate RLF-100 (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory deficiency due to COVID-19. As part of its pipeline diversification strategy, in March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle Disorders and Maple Syrup Urine Disease. In addition, Relief’s recently completed acquisitions of APR Applied Pharma Research SA and AdVita Lifescience GmbH, bring to Relief a diverse pipeline of marketed and development-stage programs.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF. For more information, visit http://www.relieftherapeutics.com. Follow Relief on LinkedIn.

References

Acer Forward-Looking Statements This press release contains forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, timelines, future financial position, future revenues, projected expenses, regulatory submissions, actions or approvals, cash position, liquidity, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the potential for our product candidates to safely and effectively treat diseases and to be approved for marketing; the commercial or market opportunity of any of our product candidates in any target indication and any territory; our ability to secure the additional capital necessary to fund our various product candidate development programs; the adequacy of our capital to support our future operations and our ability to successfully fund, initiate and complete clinical trials and regulatory submissions; the ability to protect our intellectual property rights; our strategy and business focus; and the development, expected timeline and commercial potential of any of our product candidates. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources to fund our various product candidate development programs and to meet our business objectives and operational requirements, the fact that the results of earlier studies and trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by our intellectual property, risks related to the drug development and the regulatory approval process, including the timing and requirements of regulatory actions, and the impact of competitive products and technological changes. We disclaim any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. You should review additional disclosures we make in our filings with the Securities and Exchange Commission, including our Quarterly Reports on Form 10-Q and our Annual Report on Form 10-K. You may access these documents for no charge at http://www.sec.gov.

Relief Forward-Looking Statements This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding SA and its businesses. Such statements involve certain known and unknown risks, uncertainties and other factors, including (i) whether the FDA will approve Acer’s NDA for ACER-001, (ii) whether RELIEF THERAPEUTICS Holding SA will be able to submit an application for approval of ACER-001 in Europe in Q2/Q3 2022 (or at all), (iii) whether any such application submitted to European authorities seeking marketing authorization for ACER-001 for the treatment of patient in Europe with UCDs will be approved, and (iv) those other risks, uncertainties and factors described in RELIEF THERAPEUTICS Holding SA’s annual and periodic filings with the SIX Stock Exchange, all of which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

CORPORATE CONTACTS Acer Therapeutics: Jim DeNike Acer Therapeutics Inc. jdenike@acertx.com +1 844-902-6100

RELIEF THERAPEUTICS Holding SA: Jack Weinstein Chief Financial Officer and Treasurer contact@relieftherapeutics.com

INVESTOR RELATIONS CONTACTS Acer Therapeutics: Hans Vitzthum LifeSci Advisors hans@lifesciadvisors.com +1 617-430-7578

RELIEF THERAPEUTICS Holding SA: Michael Miller Rx Communications Group mmiller@rxir.com +1-917-633-6086

See the rest here:
Acer Therapeutics and Relief Therapeutics Announce Issuance of U.S. Patent 11154521 Covering ACER-001 Formulation - Stockhouse

Posted in Molecular Genetics | Comments Off on Acer Therapeutics and Relief Therapeutics Announce Issuance of U.S. Patent 11154521 Covering ACER-001 Formulation – Stockhouse

Service and Leadership: The St. Olaf Alumni Achievement Awards, 2020 and 2021 – St. Olaf College News

Posted: October 28, 2021 at 2:49 am

Each year, St. Olaf College recognizes alumni whose service and leadership exemplify the ideals and mission of the college. In honoring these graduates for their exceptional achievements and professional contributions, they become an integral part of college history and a testament to St. Olafs tradition of excellence.The college is pleased to recognize its 2020 and 2021 alumni award recipients.2020 | Utit Choomuang 75, Amanda Cox 01, Branden Moriarity 07, Nicholas Epley 96, and Michael Solhaug 672021 | Jason DeRose 97, Kristen Rosdahl Ehresmann 84, Tony Miller 89, and David Rose 89

Animator Utit Choomuang has led a life of intellect and curiosity about the world around him. His artistic talent, work ethic, and easygoing personality sustained a distinguished career as an animator for such shows as The Simpsons and the Charlie Brown and Snoopy Show. He now lives near his childhood community in Thailand, where he is continually seeking ways to bolster the village of his ancestors.

Choomuang first came to the United States in 1971 as a Rotary Club exchange student at Northfield High School, sponsored by Sigurd Fredrickson, a music professor at St. Olaf, and his wife, Margit. They recognized his artistry, curiosity, and intellect, and helped him apply for and receive a scholarship to attend St. Olaf in the fall of 1972. Not in my wildest dreams did I think I could go to college, Choomuang says. At St. Olaf, I was allowed to dream and given the freedom to speak, think, and do. I had access to unlimited subjects and discovered the ability to think and learn for myself. He graduated in three years with a B.A. degree in art and art history.

While developing his burgeoning animation skills and learning the art of moving pictures, Choomuang was mentored by the late Professor Emeritus of Art Arch Leann, who told Choomuang he could be a filmmaker. I was fascinated that you could make a drawing walk and talk, Choomuang says. As a senior, his animated film By and Bye about his first experience flying in an airplane won first prize in a WCCO-TV film competition.

Choomuangs career as an animator has included stints with independent filmmaker Barry Nelson, CBS-TVs Charlie Brown and Snoopy Show, and Disney Televisions Goof Troop. He joined The Simpsons on a trial basis before getting paid to work in character layout, drawing images from storyboards to define a scenes action.

My first drawing of Bart walked too much like Charlie Brown, so I practiced day and night, trying to get better at drawing the Simpsons, Choomuang says. Eventually, he was promoted to overseas animation director at Akom Animation in Seoul, South Korea. Choomuang managed three subcontracted studios with hundreds of artists who were responsible for animating every frame of each episode of the show. He retired from The Simpsons after 16 years.

It was the perfect job for me, Choomuang says. Im a problem solver. I knew camera work, sound work, background, ink and paint, every aspect of animation. Im proud of having worked on a famous show.

Today, Choomuang lives in Nongnokkai, Thailand, his childhood home, which has been overdeveloped and stripped of trees by the shrimp farming industry, and devastated by a recent typhoon. After pursuing sustainable shrimp farming and reforestation efforts for several years, he now cultivates and maintains land and waters that support local farming and fishing projects. He also is developing an English immersion school for local villagers, which is currently paused due to the COVID-19 pandemic.

So many people helped me to come to the United States and to study at St. Olaf, Choomuang says. I was lucky to meet the right people at the right time, which has led to a magical life. I want to create that magic for others. Thailand is the place I know, and Ive gone home again to help people have the same chances I did.

As the New York Timess data editor, Amanda Cox leverages and presents data in reader-friendly formats, such as charts, graphs, and interactive news.

Cox got her start in journalism when she took over the humor page of St. Olafs student newspaper, The Mess. My roommate was dating the editor and I often told him the page wasnt funny, Cox says. After the students responsible for the page left abruptly over a disagreement, Cox was asked to fill in. Id see an older couple regularly read the paper together after church on Sundays, she says. The same feelings I saw watching them are now evoked in seeing my Times work being read on the subway.

Cox earned a B.A. degree in mathematics and statistics at St. Olaf and a masters degree in statistics at the University of Washington, during which she interned with the graphics department at the New York Times. She was hired as a graphics editor in 2005 before joining The Upshot in 2014, the Timess website featuring articles that combine data visualization with conventional journalistic analysis. In 2019, she was named data editor, coordinating data work across departments and serving as an adviser when questions arise about how to think about and use data thoughtfully.

Certain types of scale, context, and patterns are best understood in forms beyond words alone, Cox says.

Known for her statistical expertise and rigor, programming skills, and artistry, Coxs work has been recognized with several honors and awards in the field of data visualization. In 2012, she received the Excellence in Statistical Reporting Award from the American Statistical Association. In 2013, she gave the keynote address at the inaugural meeting of OpenVis, a conference on open-source data visualization tools and techniques. She spoke there again in 2017 and 2018.

Cox is continually imagining new ways to inform readers with data, and is proud that she has a conference room named in her honor at Google headquarters.

Behavioral scientist Nicholas Epley is the John Templeton Keller Professor of Behavioral Science and faculty director of the Center for Decision Research at the University of Chicago Booth School of Business. He also is a Neubauer Family Faculty Fellow at the university.

Epleys work in social cognition how thinking people make inferences about what other thinking people are thinking is helping us understand each other better. His experimental research focuses on investigating the accuracy of those inferences and the common mistakes we make in attempting to read other peoples minds. He is the author of Mindwise: How We Understand What Others Think, Believe, Feel, and Want.

Our beliefs and our mental states are invisible, and yet everyone makes inferences about others minds as easily as we breathe, Epley says, noting that his research has shown that people tend to use their own perceptions, biases, and egos as the basis for often incorrectly interpreting others behavior. I investigate the gaps between what we think others think of us and what they actually think of us.

Epley earned a B.A. degree in psychology and philosophy at St. Olaf. St. Olaf inspired me in academics like nothing else Ive experienced in life, he says. I was given the independence to do my own research and to pursue the things I was interested in. He conducted his first behavioral science research with psychology professors Mark Sundby and Charles Huff, publishing his first scientific paper with Huff. He also completed an independent study in moral theory studying why good people do bad things with Professor of Philosophy and Religion Edmund Santurri. We just plowed through books from Alasdair MacIntyre to Dostoevsky. Its what inspired me to become an academic, Epley says. I loved having the independence to figure out what I was interested in and to test my ideas.

Epley went on to earn a Ph.D. in psychology at Cornell University and worked as a professor in the psychology department at Harvard University before joining the Chicago Booth faculty in 2004. He teaches an ethics and well-being course to M.B.A. students called Designing a Good Life, but research remains his core focus. A recent study, conducted on Chicago public transportation, found that people who engaged in conversations with the strangers sitting next to them had a more pleasurable commute than those who did not.

Our brains are uniquely equipped to connect with the minds of others, and that connection is a major source, maybe even the dominant source, of well-being for us, Epley says. Its critical to our mental health and also surprisingly powerful for our physical health.

Epleys research, which is funded by the National Science Foundation and the Templeton Foundation, has been published in both the mainstream media and peer-reviewed journals. He is the recipient of the 2018 Career Trajectory Award from the Society for Experimental Social Psychology, the 2015 Book Prize for the Promotion of Social and Personality Science, the 2011 Distinguished Scientific Award for Early Career Contribution to Psychology from the American Psychological Association, and the 2008 Theoretical Innovation Award from the Society for Personality and Social Psychology. He was named a Professor to Watch by the Financial Times, one of the Worlds Best 40 under 40 Business School Professors by Poets and Quants, and one of the 100 Most Influential in Business Ethics in 2015 by Ethisphere.

Branden Moriarity is an associate professor in the Department of Pediatrics/Division of Pediatric Hematology and Oncology at the University of Minnesota Medical School and the director of the Moriarity Lab, which has garnered widespread attention for its cutting-edge work in preclinical drug testing, genome engineering, gene therapy, and cancer immunotherapy. The lab is known for developing novel cellular therapeutics for the treatment of cancer and genetic diseases.

Ive been interested in cancer research since I started in the sciences, Moriarity says. Everyone knows someone or is someone who has had cancer, so thats what drives me.

St. Olaf gave Moriarity his start in scientific research. While earning a B.A. degree in biology and chemistry with a concentration in biomolecular sciences, he was a research assistant in Professor of Chemistry Doug Beussmans lab and a summer Howard Hughes Medical Institute (HHMI) International Research Scholar in the Czech Republic, studying the way certain chemotherapy agents interacted with DNA and publishing a paper on his findings. He also participated in St. Olafs Biology in South India study abroad program. He went on to earn a Ph.D. in molecular, cellular, developmental biology, and genetics from the University of Minnesota Medical School in 2012, followed by a postdoctoral fellowship from 2012 to 2014.

I was taught graduate-level science at St. Olaf, especially in my upper-level courses, Moriarity says. I was surprised during my first year in graduate school to be rehashing what Id already learned. That allowed me to focus more on my research, and to propel it faster and further.

Throughout his time at St. Olaf, Moriarity was supported by TRIOs Student Support Services (SSS) program, a federally-funded, college retention program designed to help ensure academic success for first-generation students or those from low-income backgrounds.

The SSS programs impact on me was huge, and I wouldnt be where I am today without it, Moriarity says.

Moriarity also holds academic appointments in three of the University of Minnesotas graduate programs: Microbiology, Immunology, and Cancer Biology; Molecular, Cellular, Developmental Biology, and Genetics; and the Comparative and Molecular Biosciences. These are in addition to appointments in the universitys Stem Cell Institute, the Center for Genome Engineering, and the Masonic Cancer Center, at which he co-directs the Genome Engineering Shared Resource.

Moriarity has authored or co-authored more than 60 peer-reviewed publications on pediatric cancers, osteosarcomas, cancer immunotherapy, and genome engineering. Among his many awards are recent honors from the University of Minnesota, including a McKnight Land-Grant Professorship, an Early Innovator Award, and an Innovator in Translational Research Award. He has received the TRIO Achievement Award from the Midwest Federal TRIO program and Minnesotas Federal TRIO program.

In addition to his demanding research and teaching schedule, Moriarity has started three genome engineering and cancer immunotherapy biotech companies out of the University of Minnesota, including Catamaran Bio, a Boston-based startup that manufactures genetic therapies to treat cancer based on research conducted at the universitys medical school. Catamaran Bio recently raised $42 million in venture capital, a record amount for any company rooted in the universitys scientific research. Moriarity was the chief scientific officer of B-MoGen Biotechnologies, which was acquired by Minneapolis-based Bio-Techne Corporation in 2019. He currently is a founder and chief innovation officer of Luminary Therapeutics, which is focused on nonviral autologous CAR-T cell therapies.

These companies allow us to place critical focus on designing and engineering new therapies, and then getting them to the clinic safely, Moriarity says. Theyre providing hope.

Pediatric nephrologist and Vietnam War veteran Michael Solhaug has led a remarkable life of service as a humanitarian and healer. His distinguished career in pediatric medicine includes work as a clinician at Childrens Hospital of the Kings Daughters (CHKD) in Norfolk, Virginia, and as an educator and administrator at Eastern Virginia Medical School (EVMS). He was among a handful of Vietnam vets on the first Operation Smile medical missionary team to visit Vietnam in 1989 to provide corrective facial surgery to thousands of children, returning to the country on three subsequent trips with the organization in 1990, 2007, and 2014.

I was able to use my skill and my heart in a different way for the Vietnamese people, Solhaug says. The missions developed friendship and understanding between the Vietnamese and the Americans, and transformed the vets from soldiers to healers.

A talented hockey and football player, Solhaug graduated from St. Olaf with a B.S. degree in biology and chemistry in 1967 and was inducted into the St. Olaf Athletic Hall of Fame in 2007. While he focused on sports and social activities in college, Solhaug says that, in hindsight, his years at St. Olaf were incredibly formative.

I learned the innate worth of every human being and that there is vitality in honest human relationships. St. Olaf also instilled in me the importance of service to others, Solhaug says.

After graduation, Solhaug continued a family tradition of military service, enrolling in the U.S. Navys Officer Candidate School and volunteering for Swift Boat duty in Vietnam. He spent most of 1969 in command of a five-man patrol crew. He was awarded the Bronze Star with Combat V for valor during a 1969 riverine operation, and later received the Navy Commendation Medal for valor and meritorious service. He currently serves on the Swift Boat Sailors Association Board of Directors.

Solhaug says his wartime experiences in Vietnam shaped his desire to become a doctor. In an essay at the time of his 30th St. Olaf Reunion in 1997, Solhaug wrote, I witnessed the extremes of human behavior and also discovered the nobility of the human spirit especially [in] the children. [They seemed to be saying,] I am strong enough to heal, if you will be my healer.

After a stint as a middle school substitute science teacher further cemented his passion for working with children, Solhaug attended the University of Minnesota Medical School, earning an M.D. in 1975. He began his career working jointly as a specialist at CHKD and in primary care at Tidewater Childrens Associates in Virginia Beach, Virginia.

Solhaug founded CHKDs pediatric nephrology department to provide specialty care to children with acute and chronic kidney-related diseases, and has served as both its medical director and academic director. He currently is professor of physiology and professor of pediatrics at EVMS, where he has conducted National Institutes of Healthfunded research. He is vice chair of education in the Department of Physiological Sciences, and his past administrative roles include associate dean positions in academic affairs and admissions, as well as serving as president of the Faculty Senate, among others.

Medical school admissions work has been particularly satisfying for Solhaug. Helping young men and women find pathways to medicine is important to me, he says. He shares that passion with St. Olaf, mentoring students as they prepare for medical school, including 15 Oles who have attended EVMS. His service to St. Olaf also includes mentoring student-athletes, supporting the Ice Arena project, and serving as co-chair of his 50th Reunion committee.

Journalist and National Public Radio Western Bureau Chief Jason DeRose believes in the power of journalism to tell peoples stories authentically.

People should be characters in their own stories, not anecdotes, he says. Their experiences, feelings, and beliefs should be taken seriously. Public radio and other forms of nonprofit journalism are mission driven, rather than profit driven, which enables us to connect with the people at the heart of any story.

DeRose, who holds a B.A. in English and religion, magna cum laude and Phi Beta Kappa, from St. Olaf and a masters of divinity degree from the University of Chicago, has worked in radio since high school. At St. Olaf, he worked as a technical board operator at WCAL for NPRs All Things Considered, while also studying literature, history, philosophy, religion, and the arts in the interdisciplinary Great Conversation program.

Great Con was a deep dive into what it means to be human, and working at WCAL was a fantastic hands-on experience, and where I first learned how to do much of what I do now, professionally, DeRose says. During college, he interned on NPRs Washington Desk in Washington, D.C., where he also temped as a producer on All Things Considered.

As western bureau chief, DeRose oversees and edits news coverage from member station reporters and freelancers in California, Washington, Oregon, Alaska, and Hawaii. He also edits NPRs coverage of religion and LGBTQ rights. He previously was a business editor at the network during the Great Recession of 200910 and an editor on the NPR midday news program, Day to Day. Prior to joining NPR, DeRose worked as a reporter and editor at WBEZ in Chicago and KPLU in Seattle.

Over the course of his career, DeRose has reported on stories of national importance, such as views toward Islam in post9/11 America and clergy sex abuse in the Catholic Church. In covering important issues, journalism can have a lasting impact and do good in the world, he says.

While in college, DeRose also interned as an oral history interviewer at the United States Holocaust Memorial Museum and was a journalism trainer at the International Center for Journalists. He has taught journalism ethics, radio reporting, multimedia storytelling, and religion reporting at DePaul University in Chicago and at Northwestern Universitys Medill School of Journalism.

DeRose holds leadership roles at his church, St. Pauls Lutheran in Santa Monica, California, where he works with LGBTQ pastoral ministry interns. He also supervises interns at NPR and regularly teaches the art of storytelling at Holden Village, a retreat center in Washington States Cascade Mountains. He has been on Holdens board of directors since 2009.

DeRose remains engaged with St. Olaf through his friendships with several of his former professors and his participation in alumni travel programs. He recently was part of an alumni panel on journalism careers and supports both the Taylor Center for Equity and Inclusion andthe Great Conversation.

Epidemiologist Kristen Rosdahl Ehresmann has led a life of service guided by an abiding faith and servant ethic. As director of the Infectious Disease Epidemiology, Prevention, and Control Division of the Minnesota Department of Health (MDH), she believes the role of public health is to foster strong and healthy communities.

Every person matters, and we care for them, no matter their circumstances, she says. That mission fits with my faith perspective following the commandments of love the Lord your God with all your heart and love your neighbor as yourself and helps me fulfill who I was meant to be.

Ehresmann has spent her entire career at MDH, where she is currently responsible for its HIV/STD, tuberculosis, refugee health, and immunization programs, as well as its activities related to emerging infection and infection prevention and foodborne, waterborne, and zoonotic diseases. Her research and publications have focused on vaccine-preventable disease in both children and adults. She is a recipient of MDHs Achievement Award and its Star Honors Award for Exceptional Leadership.

As an educator, Ehresmann holds an adjunct faculty position at the University of Minnesota and, until 2020, held a community faculty position at Metropolitan State University, which honored her with a Faculty Excellence Award in 2009. She regularly appears in statewide media and before the state legislature to discuss public health initiatives. The liberal arts were foundational in teaching me to communicate effectively, as a large part of my job is educating others on the science of infectious diseases and their prevention, she says.

Ehresmanns team at the MDH has been particularly visible during the pandemic, assisting in the planning and coordination for the prevention, management, and mitigation of COVID-19. The work has been equally difficult and rewarding, she says. My motivation is that weve helped people be healthier by preventing disease and death.

While earning a bachelor of science degree in nursing from St. Olaf, Ehresmann studied abroad in Vellore, India. The experience piqued her interest in working in public health.

Working in India transformed my worldview and awakened my desire to get upstream, she says, referring to the health care approach that examines and addresses root causes rather than symptoms to improve outcomes. After graduation, Ehresmann volunteered for Eat Smart for Your Heart, a summer community outreach program geared toward encouraging healthy eating and activities to improve heart health, an experience that further cemented her desire to go into public health.

She has worked as a registered nurse at several hospitals and clinics and earned a masters in public health in epidemiology from the University of Minnesota in 1990. She began her career at MDH as a graduate student worker and has risen through the ranks to her current position as division director. Ive had a lot of continuity in my career, she says, noting how much shes enjoyed working with many dedicated science professionals over the years.

At the national level, Ehresmann is a member of the Association of State and Territorial Health Officials Infectious Disease Policy Committee and the National Vaccine Advisory Committee and is a liaison member of the Healthcare Infection Control Practices Advisory Committee. She also is a voting member of the Council for Outbreak Response: Healthcare-Associated Infections and Antimicrobial-Resistant Pathogens. From 2008 to 2012, Ehresmann was a voting member of the Advisory Committee on Immunization Practices.

Ehresmann has been a consistent steward of St. Olaf, hosting interns at MDH and giving lectures in the nursing program, as well as volunteering with the Piper Center for Vocation and Career for events related to health care.

David Roses peripatetic career highlights the value of his liberal arts education. Since graduating in 1989, he has been a five-time technology entrepreneur, an MIT educator, a two-time author, and an international speaker. He is an expert in digital product innovation for the Internet of things, inventing products that help millions of people every day.

Im always interested in emerging categories, Rose says. Im constantly thinking about how technology might improve peoples lives. Recently he has been working on using augmented reality to show people things they otherwise find hard to visualize or imagine, such as more sustainable landscapes or new designs for walkable cities.

Rose recently assembled a team to create ClearWater AR, the first augmented reality experience for boating and fishing. The company is developing smart tech that helps people see underwater topography and the location of fish and increases the visibility of hazard buoys in lowlight and fog.

Augmented reality can paint a Yellow Brick Road on the water to help people navigate more safely, Rose says.

Rose has worked as an innovation consultant to invent new products for Fortune 500 companies and founded five companies across the consumer electronics, health care, and social shopping industries. He was vice president for vision technology at Warby Parker, where he developed an online vision testing business and a virtual try-on app. Most recently, as a futurist at EPAM Continuum, he created prototypes with emerging technologies, such as computer vision for at-home physical therapy, and affective computing to help autonomous cars understand driver attention.

Roses computer vision company, Ditto Labs, developed tools to identify products in shared photos and videos so that people could ditto their friends and shop for similar items. His health care company, Vitality, invented the GlowCap, smart medication packaging that nudges people to take prescription medications for diabetes or transplants. His other companies have created products for digital photo sharing, interactive science museum exhibits, and smart toys like Guitar Hero and LEGO Mindstorms. His company Ambient Devices fused physical product design with digital connectivity in the Ambient Orb, which changes color to represent information, such as weather forecasts, stock market trends, energy consumption, blood sugar levels, and number of steps walked.

Rose holds a bachelors degree in physics and studio art from St. Olaf and a masters of education from Harvard University. During his time on the Hill, he sang in the St. Olaf Choir and was the photo editor of The Mess.

St. Olaf is an incredible sandbox, Rose says. I nurtured so many interests. The liberal arts made me curious and interested in diving down the rabbit hole about everything. Whether it was physics, art history, architecture, Eastern religions, or music, St. Olaf offered a depth and rigor that made each subject irresistible.

Roses first book, Enchanted Objects: Design, Human Desire, and the Internet of Things, is a blueprint for a future filled with animate everyday objects. His second book, SuperSight, explores the impact of computer vision and smart glasses. He has taught at the MITs Media Lab, Harvard Universitys Graduate School of Design, Yale Universitys Graduate School of Design, and the Copenhagen Interaction Design Institute in Denmark. He holds five patents, and his inventions have been featured at the Museum of Modern Art, in the New York Times, Wired, and the Economist, and on The Daily Show with Jon Stewart.

Entrepreneur Tony Miller is the founder and managing partner of Lemhi Ventures, which leverages venture capital to change the health care services industry. Lemhis portfolio includes 15 companies that utilize disruptive innovation, technology, and data to deliver better health outcomes, lower costs, and greater control to people over their health care decisions.

We work to change the products of health insurance, not the operating side of it, Miller says. Lemhis first two venture capital funds raised $450 million, which is fully invested. The firm is currently in the process of raising its third fund.

Until June 2021, Miller was the founder and CEO of Bind Benefits, Inc., a Lemhi-invested company that partnered with UnitedHealth Group to pioneer personalized health plans that allow people to pay for coverage and services as they need them. Previously, he was cofounder and CEO of another Lemhi-invested company, Carol Corp., which introduced health care shopping and provider comparison tools for consumers.

Miller calls himself an accidental Ole. His first choice had been to go to the University of North Carolina, but St. Olaf afforded him the chance to compete on the football and track teams for all four years. Playing sports at St. Olaf was a phenomenal experience that I wouldnt have gotten anywhere else, he says. My teammates are still some of my best friends. He earned a bachelors degree in biology and went on to earn a masters degree in kinesiology from the University of Illinois. He also holds an M.B.A. from Cornell University.

His early career includes a stint as a wellness coordinator for Medica Health Plans an experience that opened his eyes to how health insurance might be restructured, he says. He also worked at UnitedHealth Group and for Deloitte and Touche, where his main project was helping Kaiser Permanente buy and sell health plans nationwide. All of those experiences exposed me to the inner workings of the health care services industry, and how its products might be improved, Miller says. I started to wonder, What if the consumer was more in control of the dollars spent on health care? That curiosity led Miller to cofound Definity Health in 1998, which became a pioneer and national leader in consumer-driven health benefit programs, before it was sold to UnitedHealth in 2007.

Miller regularly shares career advice with St. Olaf students as a guest lecturer in St. Olafs Interim entrepreneurship class, taught by St. Olaf Entrepreneur in Residence Sian Muir.

I tell the students that even though I have a business degree, everything I apply in business I learned from the liberal arts, Miller says. Cornell taught me the hard skills of business, like finance and microeconomics, but the liberal arts foundation I got at St. Olaf helped me develop a questioning perspective that is nuanced and analytical. It taught me to have a point of view and to be purpose-driven in using my skills to be part of the solutions to societal problems.

Marla Hill Holt 88 is a regular contributor to St. Olaf Magazine.

Link:
Service and Leadership: The St. Olaf Alumni Achievement Awards, 2020 and 2021 - St. Olaf College News

Posted in Molecular Genetics | Comments Off on Service and Leadership: The St. Olaf Alumni Achievement Awards, 2020 and 2021 – St. Olaf College News

Call-and-response circuit tells neurons when to grow synapses – EurekAlert

Posted: October 28, 2021 at 2:49 am

image:Nicola Allen. view more

Credit: Salk Institute.

LA JOLLA(October 25, 2021)Brain cells called astrocytes play a key role in helping neurons develop and function properly, but theres still a lot scientists dont understand about how astrocytes perform these important jobs. Now, a team of scientists led by Associate Professor Nicola Allen has found one way that neurons and astrocytes work together to form healthy connections called synapses. This insight into normal astrocyte function could help scientists better understand disorders linked to problems with neuronal development, including autism spectrum disorders. The study was published September 8, 2021, in the journal eLife.

We know that astrocytes could play a role in neurodevelopmental disorders, so we wanted to ask: How are they playing a role in typical development? says Allen, a member of the Molecular Neurobiology Laboratory. In order to better understand the disorders, we first have to understand what happens normally.

Synapses form critical connections between neurons, allowing neurons to send signals and information throughout the body. Astrocyte cells play a role in synapse development by giving neurons directions, such as telling them when to start growing a synapse, when to stop, when to prune it back, and when to stabilize the connection.

Allen and her team took a closer look at how this process plays out in the visual cortex of the mouse brain. They sequenced the RNA of astrocytes at different stages of brain development to assess gene activity and compared it with neuronal synapse development. They found that astrocyte signaling was directly related to each stage of neuronal development. The researchers then wanted to know how the astrocytes knew to make these signals at the right time.

First, the researchers looked at what happened to the astrocytes when they changed the neurons activity. To do this, they stopped neurons from releasing a neurotransmitter called glutamate that can signal to astrocytes, and this stopped the astrocytes from showing the typical developmental changes. Next, the scientists stopped the astrocytes from responding to neurotransmitters, and found this stopped the astrocytes from expressing the right signals. With both these manipulations, the development of synapses was also disrupted, in line with the changes observed in the astrocytes.

Collectively, the findings suggest that astrocytes are responding to neurotransmitters produced by neurons to control the timing of when astrocytes produce signals to instruct neuronal development, according to Allen.

It makes sense that you have this constant feedback going on between the neuron and the astrocyte, says Allen. They are sending signals to each other: Am I in the right place? Yes, you are. Ive made a connection nowdo I keep it? Yes, you do. And they keep going back and forth.

Next, Allen and her team are studying whether these signals can be manipulatedfor example, to stimulate neurons to repair synapses or form new ones in disorders of aging, such as Alzheimers disease.

Other authors included Isabella Farhy-Tselnicker, Matthew M. Boisvert, Hanqing Liu, Cari Dowling, Galina A. Erickson, Elena Blanco-Suarez, Maxim N. Shokhirevand Joseph R. Ecker from Salk; and Chen Farhy from Sanford Burnham Prebys.

The research was supported by the National Institutes of Health, the Pew Charitable Trusts, the Chan Zuckerberg Initiative, the Howard Hughes Medical Institute and the Hearst Foundations.

About the Salk Institute for Biological Studies:

Every cure has a starting point. The Salk Institute embodies Jonas Salks mission to dare to make dreams into reality. Its internationally renowned and award-winning scientists explore the very foundations of life, seeking new understandings in neuroscience, genetics, immunology, plant biology and more. The Institute is an independent nonprofit organization and architectural landmark: small by choice, intimate by nature and fearless in the face of any challenge. Be it cancer or Alzheimers, aging or diabetes, Salk is where cures begin. Learn more at: salk.edu.

Animals

Activity-dependent modulation of synapse-regulating genes in astrocytes

8-Sep-2021

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Originally posted here:
Call-and-response circuit tells neurons when to grow synapses - EurekAlert

Posted in Molecular Genetics | Comments Off on Call-and-response circuit tells neurons when to grow synapses – EurekAlert

Government Chemist webinar: Covid and agricultural sustainability – GOV.UK

Posted: October 28, 2021 at 2:49 am

The Government Chemists vision is to provide world class measurement science to support an innovative and growing UK agrifood sector that trades sustainably on a global basis. This is achieved through the provision of impartial and unbiased technical advice and scientific measurement functions not just as a route of technical appeal for the UK Government and industry but also as a valued expert resource.

To support this vision the Government Chemist seeks to engage stakeholders through diverse events, including its webinar series.

The ultimate consequences of COVID-19 on communities, countries and the world has yet to be realised and may take years to understand fully. However, the revolution in technological innovation instigated by the research community for SARS-CoV-2 testing and in the development of a vaccine has catapulted novel approaches of use for wider human diagnostics. The pandemic has also highlighted the chasm that exists for food security in the least-developed countries, a situation which can be seen as an analogy for the agricultural sustainability challenges currently facing more developed countries.

Improvements in pathogen detection, soil analysis, genetic diversity and the utilisation of gene editing tools (such as CRISPR) for rapid modifications to plant varieties have a role to play in facilitating solutions for the future. However, there remains a disconnect between these high-level solutions and their realistic application on the ground. Accessibility to, and timeliness of delivery of, cost-effective technological advancements requires immediate action by the global agricultural community and is critical to enabling the breeders to respond to the changing demographics of their challenged communities.

This presentation will investigate how genomics, and in particular the application of novel technologies such as ultrahigh throughput (uHTP) workflows developed for diagnostic solutions to the pandemic, can play its part in providing resilience and future-proofing against climate change, population increases and possible further pandemics.

Darshna is a Senior Scientist at LGC specialising in plant genetics. She has been involved in a wide range of projects in the area of agricultural sustainability. She was the project manager for Bill and Melinda Gates Foundation - Generation Challenge Program which ensured the successful application of KASP assay genotyping as an advanced molecular marker tool for breeding programs in developing countries.

Darshna began her career at the James Hutton institute developing molecular markers for disease resistance in raspberries. Her crop development experience continued at Biogemma UK Ltd working primarily on cereal crops developing SSR methodology and SNP discovery for starch biosynthetic enzymes.

Darshna participated in the Artemisia Project funded by the Bill and Melinda Gates Foundation at York University, an important step towards understanding breeders requirements for varietal development using molecular markers in MAS. Field trial management in Kenya, Uganda, China, India and Madagascar saw the development of successful commercial varieties of Artemisia for the sustainable supply of artemisinin for Artemisinin Combination Therapy (for the treatment of malaria) production.

Darshna will be introduced by the Government Chemist, Dr Julian Braybrook.

Originally posted here:
Government Chemist webinar: Covid and agricultural sustainability - GOV.UK

Posted in Molecular Genetics | Comments Off on Government Chemist webinar: Covid and agricultural sustainability – GOV.UK

NIIMBL Welcomes 4 Industry Leaders and Adds 100 Years of Experience to the Institute – BioSpace

Posted: October 28, 2021 at 2:49 am

NEWARK, Del., Oct. 26, 2021 /PRNewswire/ --The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce that Jeffery Baker, Ph.D., Tim Charlebois, Ph.D., Roger Hart, Ph.D., and Stefanie Pluschkell, Ph.D. have recently joined the Institute as NIIMBL Senior Fellows enhancing that expertise of the organization with an additional 100 years of industry experience.

"I am excited to announce our new Senior Fellows whom all bring unique insight and expertise to NIIMBL," shares Kelvin Lee, Institute Director. Lee adds, "As we continue to grow, only 5 years since our launch, the importance of having broad-based perspectives from industry thought-leaders is critical to our community and mission."

NIIMBL is catalyzing advanced manufacturing innovations and workforce development with a membership composed of academic, industry, and non-profit stakeholders working with relevant government agencies. The NIIMBL Senior Fellows play key roles in leading various Institute initiatives such as our Process Intensification Program, Big Data Program, and Regulatory Considerations Committee, among others.

Meet the Senior Fellows:Dr. Jeff Baker is a cellular physiologist and biochemist by training. He spent over 20 years in the pharmaceutical industry supporting the development and manufacture both legacy and first in class biological products and 10 years at the United States FDA as Deputy Director of the Office of Biotechnology Products in CDER. In the latter role he received several CDER awards for his role in renewing and rebalancing OBP review, inspection, and research programs and in 2018 received an FDA Honors Award for contributions to "modernizing the U.S. regulatory system for biotechnology products through sustained creative leadership and collaboration." He was the CDER liaison to NIIMBL and the Advanced Manufacturing National Program Office at NIST. He retired from the FDA in 2021 but remains active in the biotech community and is a frequent speaker at professional conferences and a number of university programs.

Dr. Tim Charlebois retired from Pfizer after a 30-year career with the company including legacy companies Wyeth and Genetics Institute. His technical expertise and experience included molecular biology, cell line development, characterization, cGMP cell banking and testing, cell culture and drug substance process development. He was deeply involved in the development and registration of a number of early biopharmaceutical products including Recombinate (rhFVIII), BeneFIX (rhFIX), Neumega (rhIL-11), Infuse (rhBMP-2), ReFacto AF (BDDFVIII), and Enbrel (etanercept). As VP of Technology & Innovation Strategy for Biotherapeutics Pharmaceutical Sciences, he was responsible for building new business processes and a network of leaders across the organization in the areas of technology strategy and platforms, external collaborations and alliances, in- and out-licensing due diligence and business development as well as external disclosure and intellectual property. He provided leadership to Pfizer's transition into cutting-edge modalities, first with the CAR-T venture that eventually became Allogene and later with the company's major investment into AAV-based gene therapy.

Dr. Roger Hart joins NIIMBL with 30 years of experience in the biopharmaceutical field having focused on process development spanning pre-clinical molecule selection through commercial process implementation and support for protein therapeutics. Prior to joining NIIMBL, Dr. Hart was Scientific Director Process Development at Amgen responsible for external scientific collaborations within the Academic Interface and external outreach programs to universities and technology incubators. Earlier, he advanced numerous products (mAb, pepti-body, protein, small molecule) and technologies as part of the management and scientific staff at Amgen and Genentech.

Dr. Stefanie Pluschkell has over 20 years of experience in the biopharmaceutical industry. She is the Founder and CEO of InScope Coaching & Consulting LLC, providing executive leadership and career coaching as well as consulting services to corporations, academic institutions, non-profit scientific organizations, and individuals. In her most recent biopharmaceutical industry role, she was the Executive Director and Head of Business Strategy and Operations for Biotherapeutics Pharmaceutical Sciences at Pfizer Inc. In this role, she led the execution of strategic and annual business plans via matrix leadership across pharmaceutical sciences, worldwide research & development, commercial business units and manufacturing. She supported a highly diverse product portfolio, including vaccines, monoclonal antibodies, other therapeutic proteins, and advanced therapies such as gene therapy. Stefanie's team managed all laboratory and GMP facilities across the biotherapeutics pharmaceutical sciences network globally and provided the digital transformation strategy.

To learn more about NIIMBL, visitniimbl.org.

About NIIMBLThe National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is a public-private partnership whose mission is to accelerate biopharmaceutical innovation, support the development of standards that enable more efficient and rapid manufacturing capabilities, and educate and train a world-leading biopharmaceutical manufacturing workforce, fundamentally advancing U.S. competitiveness in this industry. NIIMBL is part of Manufacturing USA, a diverse network of federally-sponsored manufacturing innovation institutes, and is funded through a cooperative agreement with the National Institute of Standards and Technology (NIST) in the U.S. Department of Commerce with significant additional support from its members.

Contact:News MediaMaria X. ChaconDirector of Marketing and Communications302-831-2337mchacon@udel.edu

View original content to download multimedia:https://www.prnewswire.com/news-releases/niimbl-welcomes-4-industry-leaders-and-adds-100-years-of-experience-to-the-institute-301408980.html

SOURCE National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL)

Originally posted here:
NIIMBL Welcomes 4 Industry Leaders and Adds 100 Years of Experience to the Institute - BioSpace

Posted in Molecular Genetics | Comments Off on NIIMBL Welcomes 4 Industry Leaders and Adds 100 Years of Experience to the Institute – BioSpace

Western Australia’s nominees for the 2022 Australian of the Year Awards – Mandurah Mail

Posted: October 28, 2021 at 2:49 am

Nominees for the 2022 Western Australia Australian of the Year Awards include the founder of blue trees, a Noongar culture conservationist, a man helping migrants settle, artists shining a light disability and diversity and a man giving haircuts to the homeless.

They are among 16 WA residents in the running to be named the Western Australia Local Hero, Young Australian, Senior Australian or Australian of the Year.

The 2022 Western Australia award nominees are:

Western Australia Australian of the Year

Western Australia Young Australian of the Year

Western Australia Senior Australian of the Year

Western Australia Local Hero

The nominees are among 129 people being recognised across all states and territories as part of the program, which began in 1960.

The four award recipients from Western Australia will be announced on the evening of Thursday 4 November in a ceremony at the Westin Hotel in Perth which will also be available to watch online via livestream.

They will then join the other state and territory recipients as national finalists for the national awards announcement on January 25, 2022.

National Australia Day Council chief executive Karlie Brand congratulated the Western Australia nominees on being selected for consideration in this year's awards.

"The Western Australia nominees are achieving and contributing in many different ways," said Ms Brand.

"From grassroots community to global impact, they are making an impact."

ACM, publisher of this newspaper, is Media Partner of the 2022 Australian of the Year Awards.

The following profiles and pictures of the 16 nominees have been supplied by the National Australia Day Council, as organisers of the Australian of the Year Awards.

For more information on the Australian of the Year Awards visit australianoftheyear.org.au.

WA AUSTRALIAN OF THE YEAR - NOMINEE BIOS

Kirstin Butcher

Founder and CEO of genvis

Kirstin Butcher has led vital innovations to drive Australia's successful response to COVID-19. Through genvis - the Western Australia-based technology company she founded to drive the effectiveness of public safety teams - she has had an incredible impact on the safety of the nation.

Her innovations have powered solutions that underpin Western Australia's police and health department led COVID-19 response. From protecting borders through G2G Pass, enabling at-home quarantine for more than 100,000 individuals through G2G Now, and reducing the impact and duration of lockdowns through the SafeWA venue check-in and contact-tracing platform, Kirstin delivers high-impact public safety software.

She works tirelessly with government agencies in high-pressure, mission-critical contexts. Her success in Western Australia has set the stage for a national contribution with genvis solutions adopted in Tasmania, the Northern Territory and trialling in Victoria.

In significant ways, the lives Australians enjoy today, particularly in Western Australia, is at least in part attributable to 45 year old Kirstin's vision, tenacity and practical leadership of tangible public safety outcomes.

Julia Hales

Performance artist and disability advocate

Julia Hales is a theatre-maker and performance artist who has dedicated her career to sharing the experiences of people living with disability, in particular Down syndrome.

In 2018, Julia presented the world-premiere of You Know We Belong Together - an autobiographical play on love, relationships, acceptance and belonging experienced by a woman who also happens to have Down syndrome.

Since 2019, she's been mentored by Black Swan Theatre Company's artistic director Clare Watson. This has opened up opportunities to contribute to the theatre company and further develop her skills as a leader in the arts and disability space.

Now focused on creating artistic opportunities for other artists with disability,42 year old Julia is collaborating with My Place WA on the development of a new arts bureau called My Studio.

A passionate advocate within her community, Julia demonstrates through her art what she and others with Down syndrome are capable of. She's dispelling prejudice and creating opportunities for people like her.

Dr Scott Hollier

Co-founder and CEO of the Centre For Accessibility Australia

As the co-founder and CEO of the Centre For Accessibility Australia (CFA), Dr Scott Hollier is improving digital accessibility for people with disabilities - giving them equal access to technology and the internet.

The CFA drives impact through advocacy, research, training, auditing services and celebrations such as the Australian Access Awards. It's been instrumental in growing the accessibility movement in Australia, highlighting the people and organisations leading the way.

During COVID-19, the CFA has played a critical role in strengthening the need for digital access. Scott and his teams have worked hard to ensure no one is left behind.

Scott is also an Adjunct Senior Lecturer at Edith Cowan University. The 46 year old has been teaching the Professional Certificate in Web Accessibility course through the University of South Australia since its inception in 2011.

A great storyteller, Scott, who is also legally blind, helps people better understand accessibility issues - putting them in the shoes of those who struggle to access technology and the internet.

Paul Litherland

Cyber safety educator and campaigner

In the last five years of his career as a police officer in Western Australia, Paul Litherland worked in the force's Technology Crime Unit. While there, he became acutely aware of just how vulnerable kids were on the internet. He also felt frustration at the lack of legislation available to help fight internet crime.

In response, Paul began conducting cyber safety presentations at schools. By 2014, he'd turned his passion into a business - founding Surf Online Safe to educate teachers, students and parents about internet awareness and safety.

Today he's one of Australia's leading experts in the field. A highly sought-after speaker, 49 year old Paul has spoken at more than 550 schools and organisations across the country, sharing his cyber safety educational presentations with upwards of 250,000 people.

Paul experienced a terrible motorbike accident in 2004 where he was initially told he'd never walk or work again. Despite this, he defied the odds and has gone on to be an inspiration to many.

WA YOUNG AUSTRALIAN OF THE YEAR - NOMINEE BIOS

Sukhjit Khalsa

Spoken word artist, writer and performer

Spoken word artist, writer and performer Sukhjit Khalsa is passionate about diversity and visibility in the performing arts. Her extraordinary work provokes conversations around identity, feminism, cultural confusions, and the power of uncomfortable conversations.

Sukhjit has performed at the Sydney Opera House for the Australian Poetry Slam Competition. Her performance on Australia's Got Talent in 2016, an abridged version of her poem To Advance Australia Fair, made national headlines. One judge described the piece as "nation building" for confronting racism.

Sukhjit has toured Australia, Canada, South East Asia, the UK and the USA. The 27 year old also wrote and performed the poetry show Fully Sikh about growing up in the Perth suburbs.

Her sold-out project, Saga Sisterhood, brought together emerging female storytellers who identify as South Asian and come from non-performer backgrounds.

Sukhjit is currently working as a producer/screenwriter on projects with Screenwest and the ABC. Sukhjit and her partner were one of 10 teams to be selected for Imagine Impact Australia 2020 to develop their own rom-com series.

Tom Oliver

Activist for people with autism in the justice system

As a 20 year old with autism, Tom Oliver is dedicated to helping the vulnerable, the incarcerated and people in the autistic community.

A passionate advocate for people with autism caught up in the justice system, in March 2021, Tom presented a TEDx talk on the topic. He then worked with lawyers across Australia and globally, sharing his presentation and inspiring them to care about this very important issue.

In a recent case, Tom's involvement helped ensure a person with autism received a non-custodial sentence and therapy rather than 15 years imprisonment - not only helping the individual but other autistic and neurodiverse people.

Tom has been the recipient of scholarships and awards, including a David Goldstone Scholarship in 2021, and the Dean's Letter of Commendation in 2019. On top of that, Tom lectures at Curtin University, volunteers as a mentor, speaker, and ambassador for CoderDojo WA, a not-for-profit reaching thousands of autistic young people, and plans to open a law firm dedicated to helping people with autism in the justice system.

Dr Hayley Passmore

Child health researcher in neurodisability

Leading child health researcher, Dr Hayley Passmore is a fearless advocate for some of Western Australia's most vulnerable young people.

Hayley was part of the Telethon Kids Institute's ground-breaking Banksia Hill Detention Centre Project, which identified the prevalence of neurodisability among young people in our justice system. In response, she pioneered and delivered Reframe Training - an evidence-based intervention that helps the justice workforce better understand neurodisability and work with those affected by it.

More than 400 justice employees have completed the training course. It's also led to fundamental changes across Western Australia's youth justice system - and sparked interest from local, national and international government departments.

After overcoming her own significant health challenges, 29 year old Hayley secured funding to deliver the project to regional areas. As well as regularly training and presenting to state community organisations and service-providers, she plans to travel to South Australia and Queensland in 2022 upon request from their youth justice agencies.

Hayley was awarded a Churchill Fellowship in 2020 in recognition of her extraordinary work.

Kendall Whyte

Founder and CEO of the Blue Tree project

Kendall Whyte is the founder and CEO of Blue Tree Project, a grass-roots charity making an impact acrossAustralia. Its mission is to help spark difficult conversations and break down the stigma of mental health, by giving dead trees 'a blue lease on life'.

The Blue Tree Project is inspired by the tragic loss of Kendall's brother, Jayden, after taking his own life in 2018. The blue tree that was once painted as a practical joke now acts as a beacon of hope for those struggling, with over 700 trees now painted across Australia and the world.

Within just two years, the Blue Tree Project has helped facilitate better understanding of mental health, while providing free education seminars and creating engaging community events within regional Western Australia.

Kendall's work is helping spread the message that "it's ok to not be ok". By speaking openly and authentically, the 28 year old is helping break down the fear of judgement that stops people seeking help for mental illness.

WA SENIOR AUSTRALIAN OF THE YEAR - NOMINEE BIOS

Professor Nigel Laing AO

Winthrop Research Professor at the UWA

Professor Nigel Laing is an exceptional advocate for health, research and teaching. He has made major contributions to the field of rare genetic disorders, identifying the genetic cause for more than 30 diseases.

Nigel has also driven national initiatives such as the pre-conception screening program.

Nigel began his career as a PhD and developmental neurobiologist, researching how motor neurons and muscles interact in the developing embryo. He then re-trained in molecular genetics.

Nigel developed molecular neurogenetic research at the Australian Neuromuscular Research Institute and molecular neurogenetic diagnostics at Royal Perth Hospital. His investigations into Australian families with dominantly inherited diseases saw him identify many genetic causes - including mutations in the SOD1 gene causing familial motor neuron disease.

In 2015, Nigel was elected a Fellow of the Australian Academy of Health and Medical Sciences, and appointed an Officer of the Order of Australia (AO). A wonderful teacher and mentor, 67 year old Nigel'sunwavering desire is to improve the lives of people with genetic disorders.

Dante Maribbay

Community leader

Since arriving in Western Australia from the Philippines in 1988 with his wife and family, Dante Maribbay has been a powerhouse in Australia's Filipino community.

From assisting newly arrived migrants as they settle, to helping set up and lead associations, chairing committees, volunteering and raising funds for worthy causes, 73 year old Dante has worked ceaselessly for migrants, refugees and overseas students.

As a Grant-in-Aid Welfare Officer, Dante has advocated with other welfare officers to ensure Centrelink gives equal benefits to husbands and wives. He's also helped exploited skilled workers approach the Fair Work Ombudsman to receive unpaid salaries from ruthless employers.

Dante was a foundation member of the Western Australian Multicultural Association Inc, and a board member of the Australian Asian Association and the Ethnic Communities Council of Western Australia. As president of the Filipino Communities Council of Australia from 2016 to 2018, he represented 300,000 Filipino migrants.

Always caring of others, Dante has even opened his home to those in need.

Emeritus Professor Cheryl Praeger AC

Emeritus Professor of Mathematics at UWA

Emeritus Professor Cheryl Praeger's 40-plus year career in mathematics at the University of Western Australia (UWA) has involved everything from modern computer cryptography and secure banking, to getting images captured in outer space back to earth.

She's only the second and youngest woman in Australian history to become a professor of mathematics - doing so at age 35 and with two young children in tow. In 2019, she won Australia's most prestigious science accolade, the Prime Minister's Prize for Science.

Cheryl's work as an international academic focuses on sophisticated theoretical research in group theory - making impossibly difficult problems manageable. Its far-reaching applications include helping search engines retrieve information efficiently from the internet.

Cheryl has received honorary doctorates from universities in six countries and published more than 410 journal articles. She also ranks among the world's top 200 most highly cited mathematicians.

Now 73, Cheryl is passionate about mentoring young scientists, especially women. She has also transformed school education, encouraging more girls to study maths.

Janice Standen

President of Grandparents Rearing Grandchildren WA

Janice (Jan) Standen is president of the volunteer-run charity organisation, Grandparents Rearing Grandchildren WA (GRGWA). In this role, she advocates passionately for grandparent carers - a crucial but often ignored community in Australia.

Jan joined GRGWA in 2013 when her three grandchildren came to live with her. She knows the day-to-day battles that grandparents experience as primary carers, having lived them herself.

Against significant obstacles, Jan has driven the rapid expansion of GRGWA. She created a structure for the organisation and secured a fit-for-purpose premise, raising GRGWA's profile and increasing membership and outreach by more than 40%.

More than two-thirds of grandparent carers live in poverty. So under Jan's stewardship, GRGWA offers free legal and counselling support, a food bank pick-up centre, a donations distribution service and an op shop providing free clothing and toys. GRGWA also connects new grandparent carers to services and community.

Authentic, passionate and egalitarian, 73 year old Jan has made an outstanding contribution to the Western Australian community.

WA LOCAL HERO - NOMINEE BIOS

Visit link:
Western Australia's nominees for the 2022 Australian of the Year Awards - Mandurah Mail

Posted in Molecular Genetics | Comments Off on Western Australia’s nominees for the 2022 Australian of the Year Awards – Mandurah Mail

Vitti Labs Announces FDA Approval of IND Application for Phase II Clinical Trial of Combination Mesenchymal Stem Cell and Exosome Treatment of Novel…

Posted: October 28, 2021 at 2:48 am

LIBERTY, Mo., Oct. 26, 2021 /PRNewswire/ -- Vitti Labs (www.vittilabs.com), an AATB Accredited Tissue Bank focused on Life Science Research, Development and Manufacturing, announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to conduct Phase II Clinical Trials using a combination of Umbilical Cord Mesenchymal Stem Cell and Umbilical Cord Mesenchymal Stem Cell Exosomes for the treatment of Acute Respiratory Distress Syndrome (ARDS) associated with the Novel Corona Virus (COVID-19). This marks the very first time the FDA has approved an IND that uses both of these components together and so first of its kind therapy.

This therapy is designed to suppress the pro-inflammatory processes in the pulmonary system that occurs in COVID patients, while simultaneously alleviating pulmonary distress, such as acute lung injury and inflammation as seen in ARDS (Acute Respiratory Distress Syndrome). In addition to its anti-inflammatory and anti-fibrotic properties, the combination therapy aims to reduce oxidative stress. This Phase II study will evaluate the utility of intravenous umbilical cord mesenchymal stem cells and exosomes in mitigating the pulmonary consequences of COVID-19. As this treatment has already shown tremendous promise in the treatment for ARDS associated with COVID-19, the completion of this Phase II Clinical Trial is expected to conclude in Q1 of 2022.

Philipp Vitti, Chief Scientist of Vitti Labs, stated, "We are very excited to be the first FDA Approved IND to have Umbilical Cord Mesenchymal Stem Cells and their Exosomes being utilized together as a multi-dose combination therapy for IV use. The preliminary trials have been overwhelmingly successful. Mesenchymal Stem Cells and their exosomes have unique therapeutic benefits, and together they create advanced therapeutic properties. This application approval is a great advancement in the ongoing progress to utilize Umbilical Cord Mesenchymal Stem Cells and Exosomes for different disease models, and Vitti Labs is excited and proud to contribute their resources to finding effective treatment options for the worldwide pandemic."

Story continues

About Vitti Labs

Vitti Labs is a cGMP certified, AATB accredited Tissue bank in Liberty, Missouri. They harvest biomaterials from the umbilical cord and placenta to utilize their properties to activate and support the repair of the body. Vitti Labs has a commercial division which focuses on human cellular tissue products. Vitti Labs' research and development division focuses on understanding various disease models and utilizing umbilical cord and placental derived Mesenchymal Stem Cells and Exosomes for therapies of those diseases.

For any media requests/inquiries: Miriam McKinney, 816-200-7959, 322286@email4pr.com

http://www.vittilabs.com

Cision

View original content:https://www.prnewswire.com/news-releases/vitti-labs-announces-fda-approval-of-ind-application-for-phase-ii-clinical-trial-of-combination-mesenchymal-stem-cell-and-exosome-treatment-of-novel-corona-virus-infection-covid-19-301409076.html

SOURCE Vitti Labs

Continue reading here:
Vitti Labs Announces FDA Approval of IND Application for Phase II Clinical Trial of Combination Mesenchymal Stem Cell and Exosome Treatment of Novel...

Posted in Stem Cells | Comments Off on Vitti Labs Announces FDA Approval of IND Application for Phase II Clinical Trial of Combination Mesenchymal Stem Cell and Exosome Treatment of Novel…

Page 609«..1020..608609610611..620630..»